Morgan Lewis Strengthens Life Sciences IP Capabilities in Boston with Chad Davis, Ph.D.

BOSTON, DECEMBER 16, 2025: Morgan Lewis welcomes Chad Davis, Ph.D. as a partner in the firm’s intellectual property (IP) practice, resident in Boston. Dr. Davis joins from Dechert, bringing extensive experience in global patent portfolio strategy, patent prosecution, IP due diligence, infringement and validity analyses, post-grant proceedings, and IP-related agreements. With a doctorate in chemistry, Dr. Davis is deeply embedded in the Boston life sciences community and counsels and implements patent strategies for biotech, pharmaceutical, and chemical companies, as well as their investors, on the development, protection, and commercialization of complex scientific innovations.

“Boston continues to be a dynamic global market for life sciences innovation, and we remain committed to investing in the capabilities our clients rely on to advance their work,” said Firm Chair Jami McKeon. “Widely regarded for translating complex concepts into practical and effective IP strategies, Chad contributes cross-disciplinary insight and a client-first approach that will provide meaningful value to companies amid accelerating biotech breakthroughs, regulatory activity, and IP competition.”

Dr. Davis advises companies developing a broad range of technologies, including small molecule and biologic therapeutics, drug delivery platforms, antibodies, proteins, diagnostics, and advanced materials. He serves life sciences companies at every stage of technological development, from discovery through market entry and lifecycle management. Dr. Davis also frequently supports groundbreaking enterprises and investors through key milestones, helping to reinforce exclusivity protections and position novel scientific concepts for successful commercialization.

“Over the past year, we’ve seen significant expansion across our global IP platform—from coast-to-coast growth in the US to strengthening our teams in key UK and European jurisdictions such as London, Munich, and Paris. Chad’s life sciences patent experience aligns well with that momentum, particularly as demand for sophisticated IP counsel in Boston intensifies,” said Louis Beardell, Jr., leader of Morgan Lewis’s global IP practice. “Chad’s addition not only builds on our high-end prosecution and strategic advisory capabilities in life sciences but also enhances the collaborative work we do across our offices to support clients in highly technical and highly regulated life science sectors.”

The arrival of Dr. Davis further advances Morgan Lewis’s strategy to expand its IP and life sciences bench in the world’s leading hubs for biotechnology research and venture investment. In the past 18 months, the firm has brought on eight IP litigation partners across the Morgan Lewis IP platform in Southern California, led by Ali Razai, and the Pacific Northwest, led by Colin Heideman; an 18-member trademark team of IP lawyers and professional staff led by three partners in Washington, DC, New York, and Seattle; trademark and copyright partner Mathilde Carle in Paris; IP litigation partners Tim Powell and Hiroshi Sheraton in London; and IP litigation partners Dr. Alexander Klett, Dr. Christoph Mikyska, and Alexander Ritter in Munich. In addition, Morgan Lewis added life sciences transactions partner Luciana Griebel and, most recently, life sciences and healthcare regulatory partner Jackie Mulryne, both in London.